Compare Eli Lilly And Co (LLY) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ABRDN Physical Gold Shares ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: Eli Lilly And Co is far larger — about 147.9× ABRDN Physical Gold Shares ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| LLY | SGOL | |
|---|---|---|
Market Cap | $1.04T | $7.03B |
Volume | 3,064,878 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.28K | $51.41 |
52-Week Low | $799.57 | $37.54 |
Typical Hold Time | 93 Days | 57 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
SGOL trades at $39.31 with a 0.74% daily gain amid bearish technical signals. The stock faces resistance at $40 with support at $39. Recent gold market volatility driven by Treasury yields and Fed policy uncertainty creates headwinds. Technical indicators show 17 sell signals versus 2 buy signals, with moving averages unanimously bearish.
The outlook remains challenging with rising bond yields pressuring gold prices. Investment opportunity exists if Fed policy shifts dovish, but near-term risks include persistent inflation and higher interest rates. Stock investors should monitor Treasury yield trends and inflation data for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
